

***In the Claims:***

A complete listing of claims 1-16 with status identifier follows.

**Claims 1-14 (Cancelled)**

**Claim 15 (New)** A method of treatment for non-inflammatory pain in a mammal comprising the administering of a KCNQ2/3 potassium channel opener to said mammal, wherein said KCNQ2/3 potassium channel opener is retigabine or linopiridine.

**Claim 16 (New)** A method for the treatment of muscle relaxation, fever reduction, anxiolytic, functional bowel disorder, tinnitus, ophthalmic disease or the prevention or reduction of tolerance to a dependence inducing agent comprising a KCNQ2/3 potassium channel opener selected from the group consisting of retigabine and linopirdine.